Abingworth is a leading transatlantic life sciences investment firm. Abingworth helps transform cutting-edge science into novel medicines by providing capital and expertise to top caliber management teams building world-class companies. Since 1973, Abingworth has invested in over 180 life science companies, leading to 46 M&As and 70+ IPOs. Our therapeutic focused investments fall into three categories: seed and early-stage, development stage, and clinical co-development. Abingworth supports its portfolio companies with a team of experienced professionals at offices in London, Menlo Park (California), and Boston. Abingworth became part of Carlyle (NASDAQ: CG) on 1 August 2022.
Looking for a particular Abingworth employee's phone or email?
The Abingworth annual revenue was $17.4 million in 2026.
Tim Haines is the Managing Director and Executive Partner of Abingworth.
23 people are employed at Abingworth.
The NAICS codes for Abingworth are [541, 5239, 52, 523, 54].
The SIC codes for Abingworth are [67, 62, 679, 628].